Navigation Links
Rabbit Anti-OCT6 Polyclonal Antibody, Unconjugated from Abcam

ProductsRabbit Anti-OCT6 Polyclonal Antibody, Unconjugated from Abcam
Company Abcam
Item Rabbit Anti-OCT6 Polyclonal Antibody, Unconjugated
Price 
Description Rabbit polyclonal to Oct6 (Abpromise for all tested applications).
Antigen: Synthetic peptide conjugated to KLH derived from within residues 1 - 100 of Mouse Oct6. (Note: the amino acid sequence is proprietary) (Peptide available as ab31795.)
Entrez Gene ID: 5453
Swiss Protein ID: Q03052
Info AbcamAbcam
332 Cambridge Science Park
Milton Road
Cambridge CB4 0FW
UK







Customer Service: +44 (0) 1223 472030
Fax Number: +44 (0) 1223 472038
Web Site: http://www.abcam.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Rabbit Anti-Aph-1aL, S Loop (92-115) Polyclonal Antibody, Unconjugated from Covance Research Products, Inc
2. Rabbit Anti-Human Vitamin K-dependent Protein S (PROS1) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
3. Rabbit Anti-Human Sirtuin (silent mating type information regulation 2, S.cerevisiae, homolog) 7 (SIRT7) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
4. Rabbit Anti-Esa1 Polyclonal Antibody, Unconjugated from Abcam
5. Rabbit Anti-Human Rad51 Polyclonal Antibody, Unconjugated from Abcam
6. Human CALCA EIA (Enzyme immunoassay) Kit, Host: Rabbit ; Extraction-free from BACHEM
7. MaxArray Tissue Array (Animal - Rabbit) from Invitrogen
8. Rabbit Anti-GST Polyclonal Antibody, Unconjugated from Novus Biologicals
9. Rabbit Anti-Shigella Polyclonal Antibody, Unconjugated from GeneTex
10. Vaginal Keratinocyte Progenitors, Rabbit from CHEMICON
11. Dermal Fibroblasts, Rabbit from CHEMICON
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... 3D-ID LLC, a company engaged in biometric identification is ... technology portion of the recently awarded TIES (Technical Information ... the Army. 3D-ID LLC has a suite ... enforcement and security agencies. Gino Pereira ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... Conservation Society and other organizations released a new study ... ranching facilities in Argentina to ensure the safety of ... focus on two crocodilian species, the yacare caiman and ... ranches for sustainable harvest. The research team sought to ...
... May 13, 2010 (Toronto) A new study involving ... a gene connected with a type of intellectual disability called ... has identified this gene that, when defective, leads to Joubert ... issue of Cell . This international study combined ...
... CAMBRIDGE, Mass. -- At first glance, a diagram of the ... hopelessly complex, and efforts to control such a system futile. ... new computational model that can analyze any type of complex ... critical points that can be used to control the entire ...
Cached Biology News:Wildlife Conservation Society recommends health measures for Argentina's caiman ranches 2CAMH researcher discovers new gene that causes intellectual disability 2MIT control theory research: How to control complex networks 2MIT control theory research: How to control complex networks 3
(Date:5/30/2015)... May 30, 2015 CTI BioPharma Corp. (CTI ... business (NYSE: BAX ) today announced data from ... pacritinib for the treatment of myelofibrosis – in a ... of the American Society of Clinical Oncology (ASCO), May ... Pacritinib is an investigational oral multikinase inhibitor with ...
(Date:5/30/2015)... CHICAGO and RARITAN, N.J. ... the international, multi-center, open-label, two-part, single-arm Phase 2 ... – an investigational, human anti-CD38 monoclonal antibody – ... percent (95% CI, 20.8-38.9), as assessed by an ... multiple myeloma. The ORR was consistent among the ...
(Date:5/30/2015)... Texas , May 30, 2015  Caris ... from a study in which researchers identified biomarker ... metachronous paired glioma tumors, indicating changes in response ... observing 19 patients was a subset of a ... molecular heterogeneity of the cancer. These data utilizing ...
(Date:5/29/2015)... CHAPEL HILL, N.C. , May 29, 2015 ... the medical affairs function into roles involving clinical ... As its responsibilities have grown, Medical Affairs ... the function as a global group. And while ... sometimes find it challenging to identify strong performance ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2